Breathe Well Live Well
Condition: Asthma
Interventions: Drug: Fluticasone furoate (FF) (100 mcg); Drug: Vilanterol (VI) (25 mcg); Drug: Placebo
Sponsor: GlaxoSmithKline
Not yet recruiting – verified March 2016
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
|
GSK and Theravance file for FF/VI approval in the USA and Europe; Talks with …
The Pharma Letter Asthma (100/25mcg and 200/25mcg): The regular treatment of asthma in adults and adolescents aged 12 years and older, where use of a combination product (long-acting beta2-agonist and inhaled corticosteroid) is appropriate. • COPD (100/25mcg): The … GSK, Theravance seek approvals for FF/VI in US, Europe GSK and Theravance file next-generation Advair in USA, EU |
View full post on asthma – Google News
|
GSK and Theravance Announce Regulatory Submissions for FF/VI in the US and …
MarketWatch (press release) Asthma (100/25mcg and 200/25mcg): The regular treatment of asthma in adults and adolescents aged 12 years and older, where use of a combination product (long-acting beta2-agonist and inhaled corticosteroid) is appropriate. COPD (100/25mcg): The … GSK, Theravance unveil Regulatory Submissions for FF/VI in US, Europe GSK files key new lung drug for regulatory approval |
View full post on asthma – Google News
Condition: Asthma
Interventions: Drug: Fluticasone furoate 50 mcg (4 inhalations); Drug: Fluticasone furoate 100 mcg (4 inhalations); Drug: Fluticasone furoate 200 mcg (4 inhalations); Drug: Vilanterol 25 mcg (4 inhalations)
Sponsor: GlaxoSmithKline
Not yet recruiting – verified October 2010
View full post on ClinicalTrials.gov: “Asthma” | updated in the last 30 days